A Randomized, Double-blinded, Placebo-controlled, Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of SRN-001 in Healthy Participants
Latest Information Update: 07 Nov 2024
At a glance
- Drugs SRN-001 (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions; First in man
- Sponsors Siragen Pharmaceuticals
- 04 Nov 2024 Status changed from active, no longer recruiting to completed.
- 15 Feb 2024 Planned primary completion date changed from 12 Mar 2024 to 15 Mar 2024.
- 15 Feb 2024 Status changed from recruiting to active, no longer recruiting.